Research programme: mental disorder therapeutics - Integrative Research Laboratories

Drug Profile

Research programme: mental disorder therapeutics - Integrative Research Laboratories

Alternative Names: IRL 626; P 001

Latest Information Update: 02 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Integrative Research Laboratories
  • Class
  • Mechanism of Action Central nervous system stimulants; Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Schizophrenia
  • Research Attention-deficit hyperactivity disorder

Most Recent Events

  • 01 Mar 2016 IRL 626 is available for licensing as of 01 Mar 2016.
  • 01 Mar 2016 Early research in Attention-deficit hyperactivity disorder in Sweden (unspecified route) before March 2016
  • 01 Mar 2016 Preclinical trials in Schizophrenia in Sweden (unspecified route) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top